StockMacro
Menu

Ocugen

$0.77 -43% in 6 monthsMarket cap $260.6M

OCGN on XNAS, Health Care, Ocugen, Inc., job postings

Measures activity, not value. Not investment advice.

Short interest stands at 32% of shares while the stock fell 31% in a year and revenue dropped 11%.

  • BadFree cash flow was negative $63.9M over 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
116
Website
ocugen.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 3 Mar 2027 (an estimate: a year ago it reported on 4 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.0M, net loss $3.6M.
Quarter to 31 Dec 2021: revenue –, net income -$14.6MQuarter to 31 Mar 2022: revenue $500K, net income -$18.0MQuarter to 31 Mar 2022: revenue $500K, net income -$18.0MQuarter to 30 Jun 2022: revenue $643K, net income -$19.5MQuarter to 30 Jun 2022: revenue $643K, net income -$19.5MQuarter to 30 Sep 2022: revenue $466K, net income -$21.9MQuarter to 30 Sep 2022: revenue $466K, net income -$21.9MQuarter to 31 Dec 2022: revenue $879K, net income -$21.9MQuarter to 31 Dec 2022: revenue $879K, net income -$21.9MQuarter to 31 Mar 2023: revenue $443K, net income -$16.5MQuarter to 31 Mar 2023: revenue $443K, net income -$16.5MQuarter to 30 Jun 2023: revenue $485K, net income -$22.9MQuarter to 30 Jun 2023: revenue $485K, net income -$22.9MQuarter to 30 Sep 2023: revenue $3.7M, net income -$14.2MQuarter to 30 Sep 2023: revenue $3.7M, net income -$14.2MQuarter to 31 Dec 2023: revenue $1.4M, net income -$11.0MQuarter to 31 Dec 2023: revenue $1.4M, net income -$11.0MQuarter to 31 Mar 2024: revenue $1.0M, net income -$11.9MQuarter to 31 Mar 2024: revenue $1.0M, net income -$11.9MQuarter to 30 Jun 2024: revenue $1.1M, net income -$15.3MQuarter to 30 Jun 2024: revenue $1.1M, net income -$15.3MQuarter to 30 Sep 2024: revenue $1.1M, net income -$13.0MQuarter to 30 Sep 2024: revenue $1.1M, net income -$13.0MQuarter to 31 Dec 2024: revenue $764K, net income -$13.9MQuarter to 31 Dec 2024: revenue $764K, net income -$13.9MQuarter to 31 Mar 2025: revenue $1.5M, net income -$15.3MQuarter to 31 Mar 2025: revenue $1.5M, net income -$15.3MQuarter to 30 Jun 2025: revenue $1.4M, net income -$14.7MQuarter to 30 Jun 2025: revenue $1.4M, net income -$14.7MQuarter to 30 Sep 2025: revenue $1.8M, net income -$20.1MQuarter to 30 Sep 2025: revenue $1.8M, net income -$20.1MQuarter to 31 Dec 2025: revenue –, net income -$17.7MQuarter to 31 Mar 2026: revenue $1.5M, net income -$19.2MQuarter to 31 Mar 2026: revenue $1.5M, net income -$19.2MQuarter to 30 Jun 2026: revenue $1.5M, net income -$24.9MQuarter to 30 Jun 2026: revenue $1.5M, net income -$24.9MQuarter to 30 Sep 2026: revenue $2.0M, net income -$3.6MQuarter to 30 Sep 2026: revenue $2.0M, net income -$3.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $24.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$2.0M-$3.6M
30 Jun 2026$1.5M-$24.9M
31 Mar 2026$1.5M-$19.2M
31 Dec 2025–-$17.7M
30 Sep 2025$1.8M-$20.1M
30 Jun 2025$1.4M-$14.7M
31 Mar 2025$1.5M-$15.3M
31 Dec 2024$764K-$13.9M
30 Sep 2024$1.1M-$13.0M
30 Jun 2024$1.1M-$15.3M
31 Mar 2024$1.0M-$11.9M
31 Dec 2023$1.4M-$11.0M
30 Sep 2023$3.7M-$14.2M
30 Jun 2023$485K-$22.9M
31 Mar 2023$443K-$16.5M
31 Dec 2022$879K-$21.9M
30 Sep 2022$466K-$21.9M
30 Jun 2022$643K-$19.5M
31 Mar 2022$500K-$18.0M
31 Dec 2021–-$14.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $4.8M $5.4M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -11% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$65.4M -$64.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$63.9M -$53.5M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $84.3M $32.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $1.8M $28.4M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$82.5M (net cash) -$4.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 54.5 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 37.3 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
OcugenOCGN (this company) $260.6Mloss54.5-11%–
Eikon TherapeuticsEIKN $256.8M––––
SAB BiotherapeuticsSABS $253.1Mloss–––
Editas MedicineEDIT $253.1Mloss5.1+7.4%-145%
Kyverna TherapeuticsKYTX $269.3Mloss–––
AgenusAGEN $270.1M8.82.0+25%23.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$1.1M

bought $0, sold $1.1M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-0.7%

146 13F filers vs 147

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

43%

146.1M shares held by 13F filers (30 Sep 2026) of 339.3M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

32%

107.7M shares sold short (30 Oct 2026) of 339.3M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

16.4

107.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+0.5%

107.2M shares sold short in the report before, 107.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

58%

58% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$30K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

9

9 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.2×

9 articles in the last 7 days; its usual week has 4.

Price $0.77 on 20 Nov 2026, -31% over 12 months (12-month range $0.70 to $2.48)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $1.1M in the last 12 months (the 12 months before: $9K).
Revenue per quarter. Revenue $2.0M in the latest quarter, +11% on a year earlier.
Capital spending per quarter. Capital spending $149K in the latest quarter, +64% on a year earlier.
Institutional holders (13F filers). 146 13F filers reported holding it in the latest 13F quarter, +59% on a year earlier.
Lobbying spend. Lobbying spend: $30K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
18 Aug 2026Sharp changeShort interest spike: short interest spike, 100.9M vs usual 58.1M (2026-07-31); 1.8x the same period a year earlier
3 Jun 20268-K and other filingsDirector or officer change
14 May 20268-K and other filingsDirector or officer change
14 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 May 20268-K and other filingsA major agreement ended
9 Feb 20268-K and other filingsDirector or officer change
18 Dec 20258-K and other filingsDirector or officer change
18 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Sep 20258-K and other filingsA major agreement ended
1 Jul 20258-K and other filingsDelisting notice or listing transfer
25 Apr 20258-K and other filingsDirector or officer change
25 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Jan 20258-K and other filingsDelisting notice or listing transfer
15 Nov 20248-K and other filingsDirector or officer change
15 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Aug 2024Sharp changeShort interest spike: short interest spike, 51.3M vs usual 25.7M (2024-08-15); 2.1x the same period a year earlier
13 Aug 2024Sharp changeShort interest spike: short interest spike, 64.0M vs usual 25.4M (2024-07-31); 2.6x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 61.5M vs usual 25.4M (2024-07-15); 2.4x the same period a year earlier
16 Jul 2024Sharp changeShort interest spike: short interest spike, 53.1M vs usual 25.4M (2024-06-28); 2.0x the same period a year earlier
8 Jul 20248-K and other filingsChanged its auditor
2 Jul 2024Sharp changeShort interest spike: short interest spike, 49.1M vs usual 25.4M (2024-06-14); 1.3x the same period a year earlier
18 Jun 2024Sharp changeShort interest spike: short interest spike, 48.3M vs usual 25.4M (2024-05-31); 1.2x the same period a year earlier
6 Jun 20248-K and other filingsChanged its auditor
28 May 2024Sharp changeShort interest spike: short interest spike, 52.1M vs usual 25.4M (2024-05-15); 1.3x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 47.9M vs usual 25.4M (2024-04-30); 1.2x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 45.2M vs usual 25.4M (2024-04-15); 1.2x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 43.5M vs usual 25.4M (2024-03-28); 1.2x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 35.4M vs usual 25.4M (2024-03-15); 0.7x the same period a year earlier
1 Apr 20248-K and other filingsEarlier financial statements can no longer be relied on
1 Apr 20248-K and other filingsReport will be filed late
20 Mar 20248-K and other filingsDirector or officer change
12 Mar 2024Sharp changeShort interest spike: short interest spike, 36.6M vs usual 25.4M (2024-02-29); 0.7x the same period a year earlier
30 Jan 2024Lobbying filinglobbying engagement terminated (IKON PUBLIC AFFAIRS)
22 Jan 2024Lobbying filinglobbying engagement terminated (THE CONAFAY GROUP, LLC)
8 Jan 20248-K and other filingsDirector or officer change
8 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Nov 20238-K and other filingsDelisting notice or listing transfer
19 Sep 20238-K and other filingsDirector or officer change
15 Aug 20238-K and other filingsReport will be filed late
15 Aug 20238-K and other filingsDirector or officer change
15 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 May 20238-K and other filingsDelisting notice or listing transfer
3 May 2023Sharp changeLobbying on a new issue: lobbying on a new issue: BUD, MED (2023-03-31)
10 Mar 20238-K and other filingsDirector or officer change
6 Mar 20238-K and other filingsDirector or officer change
6 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Feb 2023Lobbying filingnew lobbying registration (THE CONAFAY GROUP, LLC)
19 Dec 2022Lobbying filingnew lobbying registration (RIDGE POLICY GROUP)
20 Jul 2022Lobbying filinglobbying engagement terminated (FTI GOVERNMENT AFFAIRS)
23 Mar 20228-K and other filingsDirector or officer change
4 Mar 20228-K and other filingsDirector or officer change
15 Dec 20218-K and other filingsDirector or officer change
15 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$600K published
Month from 1 Jan 2022: -$31K published
Month from 1 Feb 2022: -$337K published
Month from 1 Mar 2022: -$217K published
Month from 1 Apr 2022: -$21K published
Month from 1 May 2022: -$240K published
Month from 1 Jul 2022: -$427K published
Month from 1 Aug 2022: -$122K published
Month from 1 Oct 2022: -$174K published
Month from 1 Dec 2022: -$137K published
Month from 1 Jan 2023: -$128K published
Month from 1 Feb 2023: -$108K published
Month from 1 Jun 2023: $100K published
Month from 1 Nov 2024: $23K published
Month from 1 Dec 2024: $9K published
Month from 1 Jun 2026: $26K published
Month from 1 Sep 2026: -$589K published
Month from 1 Oct 2026: -$500K published
Revenue per quarter
Quarter ended 31 Mar 2022: $500K; public on 17 Apr 2024
Quarter ended 30 Jun 2022: $643K; public on 17 Apr 2024
Quarter ended 30 Sep 2022: $466K; public on 17 Apr 2024
Quarter ended 31 Dec 2022: $879K; public on 17 Apr 2024
Quarter ended 31 Mar 2023: $443K, -11% on a year earlier; public on 17 Apr 2024
Quarter ended 30 Jun 2023: $485K, -25% on a year earlier; public on 17 Apr 2024
Quarter ended 30 Sep 2023: $3.7M, +694% on a year earlier; public on 17 Apr 2024
Quarter ended 31 Dec 2023: $1.4M, +60% on a year earlier; public on 17 Apr 2024
Quarter ended 31 Mar 2024: $1.0M, +129% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $1.1M, +135% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $1.1M, -69% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $764K, -46% on a year earlier; public on 6 Mar 2025
Quarter ended 31 Mar 2025: $1.5M, +46% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $1.4M, +20% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $1.8M, +54% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $1.5M, +3.5% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $1.5M, +8.4% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $2.0M, +11% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $223K, -15% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $1.4M; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $844K; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $2.0M; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $1.6M, +623% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $2.8M, +103% on a year earlier; public on 22 Aug 2023
Quarter ended 30 Sep 2023: $3.4M, +299% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $2.7M, +34% on a year earlier; public on 17 Apr 2024
Quarter ended 31 Mar 2024: $2.4M, +46% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $513K, -82% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $507K, -85% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Mar 2025: $16K, -99% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $43K, -92% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $91K, -82% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $35K; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $6K, -62% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $21K, -51% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $149K, +64% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 108; public on 14 Feb 2022
31 Mar 2022 report: 111; public on 16 May 2022
30 Jun 2022 report: 112; public on 15 Aug 2022
30 Sep 2022 report: 114; public on 14 Nov 2022
31 Dec 2022 report: 102; public on 14 Feb 2023
31 Mar 2023 report: 96; public on 15 May 2023
30 Jun 2023 report: 83; public on 14 Aug 2023
30 Sep 2023 report: 71; public on 14 Nov 2023
31 Dec 2023 report: 61; public on 14 Feb 2024
31 Mar 2024 report: 75; public on 15 May 2024
30 Jun 2024 report: 95; public on 14 Aug 2024
30 Sep 2024 report: 113; public on 14 Nov 2024
31 Dec 2024 report: 114; public on 14 Feb 2025
31 Mar 2025 report: 108; public on 15 May 2025
30 Jun 2025 report: 97; public on 14 Aug 2025
30 Sep 2025 report: 92; public on 14 Nov 2025
31 Dec 2025 report: 106; public on 17 Feb 2026
31 Mar 2026 report: 134; public on 15 May 2026
30 Jun 2026 report: 147; public on 14 Aug 2026
30 Sep 2026 report: 146; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $190K published
Quarter from 1 Apr 2022: $235K published
Quarter from 1 Jul 2022: $125K published
Quarter from 1 Oct 2022: $105K published
Quarter from 1 Jan 2023: $115K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $60K published
Quarter from 1 Oct 2023: $90K published
Quarter from 1 Jan 2024: $60K published
Quarter from 1 Oct 2026: $30K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $500K (13 Oct 2026), 7.9× its normal reading; higher than 78% of its own history.
  • Short interest spike: had 100.9M shares sold short in the 31 Jul 2026 report, 1.8× the same report last year Public on 12 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $1.1M in the last 12 months (the 12 months before: $9K).
  • Revenue per quarter: Revenue $2.0M in the latest quarter, +11% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 78 insider trades

Last 90 days: 2 sales, $1.1M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Oct 2026Shankar MusunuriChief Executive OfficerSellplanned in advance (10b5-1)525,991$0.95$500KForm 4
11 Sep 2026Shankar MusunuriChief Executive OfficerSellplanned in advance (10b5-1)525,991$1.12$589KForm 4
17 Jun 2026Treerita Essalima Johnson-GreeneChief Financial OfficerBuy21,000$1.23$26KForm 4
2 Dec 2024Prabhavathi FernandesDirectorBuy10,000$0.91$9KForm 4
26 Nov 2024Kirsten CastilloDirectorBuy25,000$0.91$23KForm 4
16 Jun 2023Junge ZhangDirectorBuy200,278$0.50$100KForm 4
17 Feb 2023Shankar MusunuriChief Executive OfficerSellafter exercising options100,000$1.08$108KForm 4
19 Jan 2023Shankar MusunuriChief Executive OfficerSellafter exercising options100,000$1.28$128KForm 4

146 institutions reported shares at the end of Q3 2026, 43% of the shares outstanding; 20 opened a position, 21 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.27.8M8.18%$28.6M+761K+2.8%
State Street Corp19.5M5.76%$20.1M-1.9M-8.9%
Vanguard Capital Management LLC14.1M4.17%$14.6M-232K-1.6%
Millennium Management LLC12.2M3.59%$12.5M-1.8M-13%
UBS Group AG9.6M2.82%$9.8M+4.4M+85%
Geode Capital Management, LLC8.7M2.55%$8.9M-209K-2.4%
RTW Investments, LP6.7M1.96%$6.9MNo change
Two Sigma Investments, LP3.9M1.16%$4.1M+1.7M+77%
Ikarian Capital, LLC3.6M1.05%$3.7M-400K-10%
GMT Capital Corp3.5M1.03%$3.6MNo change

In 12 months: 4 director or officer changes, 4 major agreements, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
10 Nov 2026Granted Celairis Therapeutics Holdings Pty Ltd an exclusive OCU400 license for Australia and seven other countries; up to $6.1M in fees8-K
14 Oct 2026Signed a major agreement8-K
3 Jun 2026Director or officer change8-K
14 May 2026Director or officer change8-K
7 May 2026Signed a major agreement; A major agreement endedSame filing: took on new debt, sold shares privately8-K
9 Feb 2026Director or officer change8-K
21 Jan 2026Signed a major agreement8-K
18 Dec 2025Director or officer change8-K

Reported lobbying spend: $30K in Q3 2026, $60K in Q4 2023. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2023EndedIkon Public Affairsfor Ocugen IncNot statedFiling
31 Dec 2023EndedThe Conafay Group, LLCfor Ocugen, Inc.Not statedFiling
9 Feb 2023NewThe Conafay Group, LLCfor Ocugen, Inc.Seek support for R&D funding.Budget, MEDFiling
1 Dec 2022NewRidge Policy Groupfor Ocugen Inc.Legislative and regulatory issues concerning health care and innovationHealth issuesFiling
30 Jun 2022EndedFti Government Affairsfor Ocugen, Inc.Working with the Administration and Congress to discuss a response to COVID-19 pandemic.PharmacyFiling
12 Aug 2021NewFti Government Affairsfor Ocugen, Inc.Health, Chemicals and Environmental IssuesHealth issues, Environment, CHMFiling
4 Jan 2021NewIkon Public Affairsfor Ocugen IncCoronavirus vaccination programsHealth issues, MEDFiling

The 5 newest of 237 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

19 Jan 2021confirmed

Confirmed across sources Lobbying and Short interest and volume

Ocugen (OCGN): registered for federal lobbying for the first time in our data (Ikon Public Affairs), while it had 17.7M shares sold short in the 31 Dec 2020 report, 8.6× the same report last year. Two unrelated kinds of activity within 14 days.

  • Lobbying: First lobbying registration, became public on 19 Jan 2021
  • Short interest and volume: Short interest spike, became public on 13 Jan 2021
  • Short interest and volume: Short interest spike, became public on 28 Jan 2021
2019-12-31: 2.1M2020-01-15: 1.5M2020-01-31: 1.6M2020-02-14: 1.3M2020-02-28: 761K2020-03-13: 677K2020-03-31: 605K2020-04-15: 552K2020-04-30: 525K2020-05-15: 217K2020-05-29: 311K2020-06-15: 164K2020-06-30: 325K2020-07-15: 108K2020-07-31: 6.6M2020-08-14: 6.1M2020-08-31: 5.0M2020-09-15: 4.5M2020-09-30: 6.1M2020-10-15: 6.2M2020-10-30: 5.5M2020-11-13: 5.1M2020-11-30: 4.2M2020-12-15: 5.0M2020-12-31: 17.7M
The 31 Dec 2020 report against the 24 reports before it. this reportearliernormal: 1.6M
See the evidence (3 changes)

Lobbying: First lobbying registration became public on 19 Jan 2021

Ocugen registered for federal lobbying for the first time in our data (Ikon Public Affairs).

Source coverage starts
13 Jul 2010
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Short interest and volume: Short interest spike became public on 13 Jan 2021

Ocugen had 17.7M shares sold short in the 31 Dec 2020 report, 8.6× the same report last year.

This period
17.7M (the 31 Dec 2020 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+7.9
Same report last year
2.1M
History used
458 days
2019-12-31: 2.1M2020-01-15: 1.5M2020-01-31: 1.6M2020-02-14: 1.3M2020-02-28: 761K2020-03-13: 677K2020-03-31: 605K2020-04-15: 552K2020-04-30: 525K2020-05-15: 217K2020-05-29: 311K2020-06-15: 164K2020-06-30: 325K2020-07-15: 108K2020-07-31: 6.6M2020-08-14: 6.1M2020-08-31: 5.0M2020-09-15: 4.5M2020-09-30: 6.1M2020-10-15: 6.2M2020-10-30: 5.5M2020-11-13: 5.1M2020-11-30: 4.2M2020-12-15: 5.0M2020-12-31: 17.7M
the 31 Dec 2020 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jan 2021

Ocugen had 14.8M shares sold short in the 15 Jan 2021 report, 9.6× the same report last year.

This period
14.8M (the 15 Jan 2021 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+6.2
Same report last year
1.5M
History used
473 days
2020-01-15: 1.5M2020-01-31: 1.6M2020-02-14: 1.3M2020-02-28: 761K2020-03-13: 677K2020-03-31: 605K2020-04-15: 552K2020-04-30: 525K2020-05-15: 217K2020-05-29: 311K2020-06-15: 164K2020-06-30: 325K2020-07-15: 108K2020-07-31: 6.6M2020-08-14: 6.1M2020-08-31: 5.0M2020-09-15: 4.5M2020-09-30: 6.1M2020-10-15: 6.2M2020-10-30: 5.5M2020-11-13: 5.1M2020-11-30: 4.2M2020-12-15: 5.0M2020-12-31: 17.7M2021-01-15: 14.8M
the 15 Jan 2021 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 12 Aug 2026Short interest and volume change

    had 100.9M shares sold short in the 31 Jul 2026 report, 1.8× the same report last year.

    Same report last year: 54.8M; its normal report is 58.1M.

    See the evidence
    This period
    100.9M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    58.1M
    Typical spread (median absolute deviation)
    7.1M
    How far from its usual level
    +4.1
    Same report last year
    54.8M
    History used
    2,496 days
    2025-07-31: 54.8M2025-08-15: 55.2M2025-08-29: 54.5M2025-09-15: 54.1M2025-09-30: 52.8M2025-10-15: 58.1M2025-10-31: 58.0M2025-11-14: 59.1M2025-11-28: 59.5M2025-12-15: 59.0M2025-12-31: 46.4M2026-01-15: 47.9M2026-01-30: 47.3M2026-02-13: 49.1M2026-02-27: 50.6M2026-03-13: 52.4M2026-03-31: 64.8M2026-04-15: 67.9M2026-04-30: 69.7M2026-05-15: 81.0M2026-05-29: 83.0M2026-06-15: 86.6M2026-06-30: 105.4M2026-07-15: 100.6M2026-07-31: 100.9M
    the 31 Jul 2026 report24 earlier reportsnormal: 58.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 18 Jun 2026Insiders record

    Johnson-Greene Treerita Essalima (Chief Financial Officer) bought 21,000 shares of OCGN ($25,830) (dated 17 Jun 2026)

  3. 3 Jun 2026Filings record

    Director or officer change

  4. 14 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 14 May 2026Filings record

    Director or officer change

  6. 7 May 2026Filings record

    A major agreement ended

  7. 9 Feb 2026Filings record

    Director or officer change

  8. 18 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 18 Dec 2025Filings record

    Director or officer change

  10. 18 Sep 2025Filings record

    A major agreement ended

  11. 1 Jul 2025Filings record

    Delisting notice or listing transfer

  12. 25 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 25 Apr 2025Filings record

    Director or officer change

  14. 3 Jan 2025Filings record

    Delisting notice or listing transfer

  15. 3 Dec 2024Insiders record

    Fernandes Prabhavathi (director) bought 10,000 shares of OCGN ($9,100) (dated 2 Dec 2024)

  16. 27 Nov 2024Insiders record

    Castillo Kirsten (director) bought 25,000 shares of OCGN ($22,750) (dated 26 Nov 2024)

  17. 15 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 15 Nov 2024Filings record

    Director or officer change

  19. 27 Aug 2024Short interest and volume change

    had 51.3M shares sold short in the 15 Aug 2024 report, 2.1× the same report last year.

    Same report last year: 24.7M; its normal report is 25.7M.

    See the evidence
    This period
    51.3M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    25.7M
    Typical spread (median absolute deviation)
    2.8M
    How far from its usual level
    +6.1
    Same report last year
    24.7M
    History used
    1,781 days
    2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M2024-04-30: 47.9M2024-05-15: 52.1M2024-05-31: 48.3M2024-06-14: 49.1M2024-06-28: 53.1M2024-07-15: 61.5M2024-07-31: 64.0M2024-08-15: 51.3M
    the 15 Aug 2024 report24 earlier reportsnormal: 25.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 10 Aug 2024Short interest and volume change

    had 64.0M shares sold short in the 31 Jul 2024 report, 2.6× the same report last year.

    Same report last year: 24.8M; its normal report is 25.4M.

    See the evidence
    This period
    64.0M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +14.2
    Same report last year
    24.8M
    History used
    1,766 days
    2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M2024-04-30: 47.9M2024-05-15: 52.1M2024-05-31: 48.3M2024-06-14: 49.1M2024-06-28: 53.1M2024-07-15: 61.5M2024-07-31: 64.0M
    the 31 Jul 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 25 Jul 2024Short interest and volume change

    had 61.5M shares sold short in the 15 Jul 2024 report, 2.4× the same report last year.

    Same report last year: 25.4M; its normal report is 25.4M.

    See the evidence
    This period
    61.5M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +14.2
    Same report last year
    25.4M
    History used
    1,750 days
    2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M2024-04-30: 47.9M2024-05-15: 52.1M2024-05-31: 48.3M2024-06-14: 49.1M2024-06-28: 53.1M2024-07-15: 61.5M
    the 15 Jul 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 11 Jul 2024Short interest and volume change

    had 53.1M shares sold short in the 28 Jun 2024 report, 2.0× the same report last year.

    Same report last year: 26.9M; its normal report is 25.4M.

    See the evidence
    This period
    53.1M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +10.9
    Same report last year
    26.9M
    History used
    1,733 days
    2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M2024-04-30: 47.9M2024-05-15: 52.1M2024-05-31: 48.3M2024-06-14: 49.1M2024-06-28: 53.1M
    the 28 Jun 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 8 Jul 2024Filings record

    Changed its auditor

  24. 27 Jun 2024Short interest and volume change

    had 49.1M shares sold short in the 14 Jun 2024 report, 1.3× the same report last year.

    Same report last year: 37.3M; its normal report is 25.4M.

    See the evidence
    This period
    49.1M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +9.3
    Same report last year
    37.3M
    History used
    1,719 days
    2023-06-15: 37.3M2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M2024-04-30: 47.9M2024-05-15: 52.1M2024-05-31: 48.3M2024-06-14: 49.1M
    the 14 Jun 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 12 Jun 2024Short interest and volume change

    had 48.3M shares sold short in the 31 May 2024 report, 1.2× the same report last year.

    Same report last year: 41.8M; its normal report is 25.4M.

    See the evidence
    This period
    48.3M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +9.0
    Same report last year
    41.8M
    History used
    1,705 days
    2023-05-31: 41.8M2023-06-15: 37.3M2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M2024-04-30: 47.9M2024-05-15: 52.1M2024-05-31: 48.3M
    the 31 May 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 6 Jun 2024Filings record

    Changed its auditor

  27. 25 May 2024Short interest and volume change

    had 52.1M shares sold short in the 15 May 2024 report, 1.3× the same report last year.

    Same report last year: 40.8M; its normal report is 25.4M.

    See the evidence
    This period
    52.1M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +10.5
    Same report last year
    40.8M
    History used
    1,689 days
    2023-05-15: 40.8M2023-05-31: 41.8M2023-06-15: 37.3M2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M2024-04-30: 47.9M2024-05-15: 52.1M
    the 15 May 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 10 May 2024Short interest and volume change

    had 47.9M shares sold short in the 30 Apr 2024 report, 1.2× the same report last year.

    Same report last year: 40.0M; its normal report is 25.4M.

    See the evidence
    This period
    47.9M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +8.9
    Same report last year
    40.0M
    History used
    1,674 days
    2023-04-28: 40.0M2023-05-15: 40.8M2023-05-31: 41.8M2023-06-15: 37.3M2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M2024-04-30: 47.9M
    the 30 Apr 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 25 Apr 2024Short interest and volume change

    had 45.2M shares sold short in the 15 Apr 2024 report, 1.2× the same report last year.

    Same report last year: 37.5M; its normal report is 25.4M.

    See the evidence
    This period
    45.2M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +7.8
    Same report last year
    37.5M
    History used
    1,659 days
    2023-04-14: 37.5M2023-04-28: 40.0M2023-05-15: 40.8M2023-05-31: 41.8M2023-06-15: 37.3M2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M2024-04-15: 45.2M
    the 15 Apr 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 10 Apr 2024Short interest and volume change

    had 43.5M shares sold short in the 28 Mar 2024 report, 1.2× the same report last year.

    Same report last year: 37.1M; its normal report is 25.4M.

    See the evidence
    This period
    43.5M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +7.1
    Same report last year
    37.1M
    History used
    1,641 days
    2023-03-31: 37.1M2023-04-14: 37.5M2023-04-28: 40.0M2023-05-15: 40.8M2023-05-31: 41.8M2023-06-15: 37.3M2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M2024-03-28: 43.5M
    the 28 Mar 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 1 Apr 2024Filings record

    Earlier financial statements can no longer be relied on

  32. 1 Apr 2024Filings record

    Report will be filed late

  33. 27 Mar 2024Short interest and volume change

    had 35.4M shares sold short in the 15 Mar 2024 report, 30% below the same report last year.

    Same report last year: 50.9M; its normal report is 25.4M.

    See the evidence
    This period
    35.4M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +3.9
    Same report last year
    50.9M
    History used
    1,628 days
    2023-03-15: 50.9M2023-03-31: 37.1M2023-04-14: 37.5M2023-04-28: 40.0M2023-05-15: 40.8M2023-05-31: 41.8M2023-06-15: 37.3M2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M2024-03-15: 35.4M
    the 15 Mar 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 20 Mar 2024Filings record

    Director or officer change

  35. 12 Mar 2024Short interest and volume change

    had 36.6M shares sold short in the 29 Feb 2024 report, 26% below the same report last year.

    Same report last year: 49.5M; its normal report is 25.4M.

    See the evidence
    This period
    36.6M (the 29 Feb 2024 report)
    Normal report (median of 24 earlier)
    25.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +4.4
    Same report last year
    49.5M
    History used
    1,613 days
    2023-02-28: 49.5M2023-03-15: 50.9M2023-03-31: 37.1M2023-04-14: 37.5M2023-04-28: 40.0M2023-05-15: 40.8M2023-05-31: 41.8M2023-06-15: 37.3M2023-06-30: 26.9M2023-07-14: 25.4M2023-07-31: 24.8M2023-08-15: 24.7M2023-08-31: 25.5M2023-09-15: 24.3M2023-09-29: 25.2M2023-10-13: 25.4M2023-10-31: 24.7M2023-11-15: 25.2M2023-11-30: 23.8M2023-12-15: 22.3M2023-12-29: 23.5M2024-01-12: 25.9M2024-01-31: 23.7M2024-02-15: 24.4M2024-02-29: 36.6M
    the 29 Feb 2024 report24 earlier reportsnormal: 25.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 30 Jan 2024Lobbying record

    OCUGEN INC: lobbying engagement terminated (IKON PUBLIC AFFAIRS) (dated 31 Dec 2023)

  37. 22 Jan 2024Lobbying record

    OCUGEN, INC.: lobbying engagement terminated (THE CONAFAY GROUP, LLC) (dated 31 Dec 2023)

  38. 8 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 8 Jan 2024Filings record

    Director or officer change

  40. 1 Nov 2023Filings record

    Delisting notice or listing transfer

Showing the newest 40 of 139 entries; narrow the window or the kind of data to see older ones.

Not listed: 306 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001372299
Ticker
OCGN
Domain
ocugen.com
Employer name
Ocugen OpCo, Inc. (1 unverified)
Fein
46-3679209 (1 unverified)
Hq location
PA|MALVERN|19355 (1 unverified)
Lobbying client
ocugen
Name
HISTOGENICS CORP, Histogenics Securities Corporation, Ocugen Canada Ltd, Ocugen, Inc. and 3 more
Wikidata
Q106698278
  • DOL H-1B labor condition applications and PERM certifications2 data points13 Jul 2026 to 13 Jul 2026
  • Federal lobbying disclosures (LDA)7 records, 39 data points4 Jan 2021 to 30 Sep 2026
  • SEC Form 13F institutional holdings261 data points30 Sep 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)317 records10 Mar 2016 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)723 data points31 Dec 2013 to 30 Oct 2026
  • SEC Form 4 insider transactions78 records, 232 data points3 Oct 2016 to 13 Oct 2026
  • FINRA short interest (twice monthly)510 data points30 Sep 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3594 data points30 Sep 2019 to 20 Nov 2026